Patents by Inventor Luke O'Connor

Luke O'Connor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180244734
    Abstract: An isolated protein from Cimex lectularius comprising an amino acid sequence selected from any one of SEQ ID No. 1 or 5 or fragment thereof or an isolated polypeptide from Cimex lectularius comprising an amino acid sequence selected from any one or more of SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 6 and SEQ ID No. 7 or fragment thereof for use in generating antibodies to detect the presence of antigens specific for Cimex lectularius wherein the antibodies are capable of detecting Cimex lectularius antigen in all stages of Cimex lectularius development from egg, nymphs, moults to mature male and female adults at antigen concentrations of less than 2 ?g/ml.
    Type: Application
    Filed: August 31, 2016
    Publication date: August 30, 2018
    Inventors: Natasha GORDON, Luke O'SHAUGHNESSY, Bruce MITCHELL
  • Publication number: 20180044287
    Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.
    Type: Application
    Filed: February 16, 2016
    Publication date: February 15, 2018
    Inventors: Luke O'NEILL, Rebecca COLL, Matthew COOPER, Avril ROBERTSON, Kate SCHRODER
  • Patent number: 9234046
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of renal disease and inflammation. In particular the invention provides methods for the treatment of kidney disease and failure through the administration of compounds which function as inhibitors of TLR2 function and expression.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: January 12, 2016
    Assignee: OPSONA Therapeutics Ltd
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher
  • Patent number: 9038230
    Abstract: A cleaning device for a safety razor having single or multiple parallel blades is disclosed. A hollow connector is affixed to a water tap of a bathroom sink allowing water to flow therethrough into a body depending from the connector, rotating a brush held in the body and exiting through a slot in the body. The shaving head of the razor is positioned with the slot such that the blades within the head are embedded within the bristles of the brush. As the brush rotates, its bristles remove shaving debris from between the blades and immediate surrounds. After use, the device can easily be disassembled to facilitate cleaning of all components thereof.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: May 26, 2015
    Inventor: Luke O'Neill
  • Publication number: 20140304928
    Abstract: A cleaning device for a safety razor having single or multiple parallel blades is disclosed. A hollow connector is affixed to a water tap of a bathroom sink allowing water to flow therethrough into a body depending from the connector, rotating a brush held in the body and exiting through a slot in the body. The shaving head of the razor is positioned with the slot such that the blades within the head are embedded within the bristles of the brush. As the brush rotates, its bristles remove shaving debris from between the blades and immediate surrounds. After use, the device can easily be disassembled to facilitate cleaning of all components thereof.
    Type: Application
    Filed: September 25, 2012
    Publication date: October 16, 2014
    Inventor: Luke O'Neill
  • Publication number: 20140234252
    Abstract: The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the NLRP3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation. The invention is also directed to a method for the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation and to recombinant vectors and recombinant proteins for use in such methods. The present invention also provides a method for determining the risk of developing or monitoring the progression of diseases involving drusen and anaphylatoxin-induced choroidal neo-vascularisation.
    Type: Application
    Filed: October 1, 2012
    Publication date: August 21, 2014
    Inventors: Matthew Campbell, Peter Humphries, Marian Humphries, Anna-Sophia Kiang, Sarah Doyle, Luke O'neill
  • Patent number: 8734788
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of ischemia reperfusion injury. In particular the invention provides compounds which function to suppress Toll-like Receptor 2 biological function or expression.
    Type: Grant
    Filed: August 4, 2008
    Date of Patent: May 27, 2014
    Assignee: OPSONA Therapeutics Ltd
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher, Dominique De Kleijn, Fatih Arslan, Gerard Pasterkamp
  • Patent number: 8700540
    Abstract: In one embodiment, a method includes accessing a plurality of event listings, accessing event information associated with the event listings, accessing social network information associated with a particular user, and ranking the event listings for the particular user based at least in part on the social network information and event information.
    Type: Grant
    Filed: November 29, 2010
    Date of Patent: April 15, 2014
    Assignee: Eventbrite, Inc.
    Inventors: Brian Richard Zambrano, Luke O'Daniel Groesbeck
  • Patent number: 8580255
    Abstract: The present invention provides compositions and methods for the treatment of autoimmune diseases, in particular rheumatoid arthritis. Compounds which function as antagonists of Toll-like Receptor 2 are shown to suppress the immune response which result in the onset and progression of autoimmune disease. In particular monoclonal antibodies which have a binding specificity to Toll-like receptor 2 are disclosed for use in methods for the treatment and/or prophylaxis of autoimmune disease.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: November 12, 2013
    Assignee: OPSONA Therapeutics Ltd
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher
  • Publication number: 20130227011
    Abstract: In one embodiment, a method includes accessing a graph structure comprising a plurality of nodes and edges connecting the nodes, determining a similarity score for each node with respect to a first node, ranking each of the nodes based on their respective similarity score, selecting a set of nodes based on the ranking of each node, and identifying one or more event associated with the selected set of nodes.
    Type: Application
    Filed: February 29, 2012
    Publication date: August 29, 2013
    Applicant: Eventbrite, Inc.
    Inventors: Vipul Sharma, Eyal Reuveni, Brian Richard Zambrano, Luke O'Daniel Groesbeck
  • Patent number: 8414887
    Abstract: The present invention relates to compositions and methods for use in the treatment of conditions such as septicaemia and septic shock. The invention further provides compositions and methods for the suppression Toll-like Receptor 4 mediated activation of the immune system. The invention further provides screening assays to identify compounds which have utility in the foregoing compositions and methods.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: April 9, 2013
    Assignee: Opsona Therapeutics Limited
    Inventors: Luke O'Neill, Susan Carpenter, Aisling Dunne
  • Publication number: 20120258103
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of renal disease and inflammation. In particular the invention provides methods for the treatment of kidney disease and failure through the administration of compounds which function as inhibitors of TLR2 function and expression.
    Type: Application
    Filed: June 19, 2012
    Publication date: October 11, 2012
    Applicant: OPSONA Therapeutics Ltd
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher
  • Publication number: 20120141466
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of ischemia reperfusion injury. In particular the invention provides compounds which function to suppress Toll-like Receptor 2 biological function or expression.
    Type: Application
    Filed: August 4, 2008
    Publication date: June 7, 2012
    Applicant: Opsona Therapeutics Ltd
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher, Dominique De Kleijn, Fatih Arslan, Gerard Pasterkamp
  • Publication number: 20110293601
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of ischemia reperfusion injury. In particular the invention provides compounds which function to suppress Toll-like Receptor 2 biological function or expression.
    Type: Application
    Filed: August 4, 2008
    Publication date: December 1, 2011
    Applicant: Opsona Therapeutics Ltd
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher, Dominique De Kleijn, Fatih Arslan, Gerard Pasterkamp
  • Patent number: 7847696
    Abstract: For detecting a blocker RFID tag, the following steps are conducted. First, a random identifier of a given bit length is created. Alternatively, an identifier is selected out of a probing set, which is stored on a data storage device. The probing set comprises of identifiers, which are not being used as identifiers for a given set of RFID tags. In a second step, a response from all RFID tags is requested having an identifier matching the random identifier or, respectively, the selected identifier. In a third step, it is determined, depending on receiving or not receiving a response, whether the blocker RFID tag is present.
    Type: Grant
    Filed: August 12, 2008
    Date of Patent: December 7, 2010
    Assignee: International Business Machines Corporation
    Inventors: Guenter Karjoth, Luke O'Connor, Michael Backes
  • Publication number: 20100278817
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of renal disease and inflammation. In particular the invention provides methods for the treatment of kidney disease and failure through the administration of compounds which function as inhibitors of TLR2 function and expression.
    Type: Application
    Filed: July 4, 2008
    Publication date: November 4, 2010
    Applicant: OPSONA Therapeutics Ltd.
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher
  • Publication number: 20100247527
    Abstract: The present invention provides compositions and methods for the treatment of autoimmune diseases, in particular rheumatoid arthritis. Compounds which function as antagonists of Toll-like Receptor 2 are shown to suppress the immune response which result in the onset and progression of autoimmune disease. In particular monoclonal antibodies which have a binding specificity to Toll-like receptor 2 are disclosed for use in methods for the treatment and/or prophylaxis of autoimmune disease.
    Type: Application
    Filed: June 27, 2008
    Publication date: September 30, 2010
    Applicant: Opsona Therapeutics Ltd.
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Koegh, Christopher Locher
  • Publication number: 20080316001
    Abstract: For detecting a blocker RFID tag, the following steps are conducted. First, a random identifier of a given bit length is created. Alternatively, an identifier is selected out of a probing set, which is stored on a data storage device. The probing set comprises of identifiers, which are not being used as identifiers for a given set of RFID tags. In a second step, a response from all RFID tags is requested having an identifier matching the random identifier or, respectively, the selected identifier. In a third step, it is determined, depending on receiving or not receiving a response, whether the blocker RFID tag is present.
    Type: Application
    Filed: August 12, 2008
    Publication date: December 25, 2008
    Inventors: Guenter Karjoth, Luke O'Connor, Michael Backes
  • Publication number: 20070194879
    Abstract: For detecting an invalid RFID tag, an identifier and authentication information is read from a given RFID tag. The authentication information is then verified dependent on at least a given part (IDP_TAG) of the identifier (ID_TAG) and it is determined that the given RFID tag is the invalid RFID tag if the verification was negative. Accordingly, an RFID tag is manufactured by determining an identifier (ID), determining an authentication information dependent on at least a given part (IDP) of the identifier (ID) and storing the identifier (ID) and the authentication information on or in the RFID tag.
    Type: Application
    Filed: May 2, 2006
    Publication date: August 23, 2007
    Applicant: International Business Machines Corporation
    Inventors: Michael Backes, Christian Cachin, Sastry Duri, Guenter Karjoth, Luke O'Connor
  • Publication number: 20070125523
    Abstract: A computer assembly including a casing having a bottom and end walls and side walls and a lid and a variety of computer components are supported on the bottom. A partition extends between the side walls and a plurality of fans is disposed in the partition for moving air through perforations in the end walls. A heat exchanger includes fins and each fan has a central hub and fan blades extending radially therefrom. In the embodiment of FIGS. 1 and 2, the fans move air into said fins and a flow straightener is disposed between the hub of each fan and the fins for straightening flow downstream of the hub prior to entering said fins. In the embodiment of FIGS. 3 and 4, the fans move air through the fins and into a flow deflector over each hub of the fan for diverting flow from the fins and around the hubs prior to entering the fans.
    Type: Application
    Filed: December 1, 2005
    Publication date: June 7, 2007
    Inventors: Mohinder Bhatti, Ilya Reyzin, Luke O'Dwyer